Editas Medicine (Editas Medicine) Price-to-Tangible-Book : 1.25 (As of Apr. 27, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Price-to-Tangible-Book?

As of today (2024-04-27), Editas Medicine's share price is $5.32. Editas Medicine's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $4.27. Hence, Editas Medicine's Price to Tangible Book Ratio of today is 1.25.

The historical rank and industry rank for Editas Medicine's Price-to-Tangible-Book or its related term are showing as below:

EDIT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.22 Med: 4.51 Max: 11.14
Current: 1.25

During the past 11 years, Editas Medicine's highest Price to Tangible Book Ratio was 11.14. The lowest was 1.22. And the median was 4.51.

EDIT's Price-to-Tangible-Book is ranked better than
77.46% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs EDIT: 1.25

A closely related ratio is called PB Ratio. As of today, Editas Medicine's share price is $5.32. Editas Medicine's Book Value per Sharefor the quarter that ended in Dec. 2023 was $4.27. Hence, Editas Medicine's P/B Ratio of today is 1.25.

Editas Medicine Price-to-Tangible-Book Historical Data

The historical data trend for Editas Medicine's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Price-to-Tangible-Book Chart

Editas Medicine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

6.13

11.14

3.28

1.69

2.37

Editas Medicine Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															1.69	1.58	1.68	1.77	2.37

Competitive Comparison of Editas Medicine's Price-to-Tangible-Book

For the Biotechnology subindustry, Editas Medicine's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Editas Medicine's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Price-to-Tangible-Book falls into.

Editas Medicine Price-to-Tangible-Book Calculation

Editas Medicine's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	5.32	/	4.269
	=	1.25

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Editas Medicine Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Editas Medicine (Editas Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

8EM:Germany 8EM:Germany

Address

11 Hurley Street, Cambridge, MA, USA, 02141

Website

https://www.editasmedicine.com

Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Executives

Bruce Eaton	officer: EVP, Chief Business Officer	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Linda Burkly	officer: EVP, CHIEF SCIENTIFIC OFFICER	1 MAIN STREET, CAMBRIDGE MA 02142
Baisong Mei	officer: SVP, CHIEF MEDICAL OFFICER	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill	director, officer: CEO	215 FIRST STREET, CAMBRIDGE MA 02142
Erick Lucera	officer: EVP, CHIEF FINANCIAL OFFICER	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Michelle Robertson	officer: Chief Financial Officer	C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman	officer: EVP, Chief Scientific Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels	officer: EVP/Chief Medical Officer	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton	director	C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen	director	940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142